Biogen’s Q2 earnings smashed expectations with $2.74 billion in sales and profit soaring 80% above forecasts, prompting a bullish full-year outlook. Strong global demand for high-dose SPINRAZA, plus solid contributions from newly acquired Apellis drugs SYFOVRE and Empaveli, signal a shift away from legacy MS treatments toward explosive growth. CEO praise for seamless integration and a new home-dosing Alzheimer’s option further fuel investor optimism. With five late-stage trials in lupus, rare seizures, and more, Biogen is aggressively expanding into immunology and beyond—backed by R&D investments and anticipated cost savings from the Apellis deal. The future looks packed with momentum.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
